TB-500 is the synthetic research analogue of a 44-amino-acid sequence fragment of thymosin beta-4, a naturally occurring protein originally isolated from bovine thymus tissue. It is among the most extensively studied repair-related peptides in animal model research, with publications spanning muscle injury, tendon repair, cardiac protection, and neurological recovery.
For European researchers — in Germany, the Netherlands, France, Belgium, and across the EU — accessing TB-500 from a reliable, compliant EU warehouse has become the standard approach in 2026.
The Research Case for TB-500
Origin and natural biology
Thymosin beta-4 (Tβ4) is a ubiquitous protein found in virtually every nucleated cell in the human body. It plays a central role in actin cytoskeleton organisation — regulating the polymerisation and depolymerisation of G-actin monomers into F-actin filaments. This function underlies its involvement in cell migration, which is fundamental to tissue repair processes.
TB-500 is a synthetic peptide corresponding to a biologically active fragment of Tβ4: specifically the LKKTETQ region, which contains the actin-binding domain responsible for many of the compound’s studied effects.
Published evidence
Wound healing and tissue repair
Multiple rodent studies have documented TB-500’s effects in wound healing models:
- Accelerated skin wound closure — associated with enhanced keratinocyte and fibroblast migration
- Increased angiogenesis at wound sites — new vessel formation supporting tissue oxygenation
- Modulation of inflammatory cytokines: reduced IL-6 and TNF-alpha at wound sites
Tendon and ligament research
- Enhanced healing of partial tendon injuries in rat models (Spurney et al., J Cardiovasc Pharmacol, 2010)
- Upregulation of collagen deposition in healing tendon tissue
- Reduced scarring and improved mechanical properties of healed tissue in several studies
Cardiac research
A specific body of research has investigated Tβ4 and TB-500 in cardiac injury models:
- Improved cardiac function following experimental myocardial infarction in mouse models
- Activation of cardiac progenitor cells and cardiomyocyte survival pathways
- Reduction in infarct size in several rodent MI studies (Bock-Marquette et al., Nature, 2004)
Neurological recovery
- Neuroprotective effects in stroke models — reduced ischaemic damage in rodent cerebral ischaemia studies
- Enhanced oligodendrocyte differentiation in models of demyelination
- Investigated in traumatic brain injury models for neuroinflammation reduction
TB-500 Across European Research Markets
Germany
German researchers studying musculoskeletal repair, sports injury, and cardiac models represent a significant portion of European TB-500 demand. Research institutions in Munich, Berlin, and Heidelberg operate active programmes in tissue engineering and regenerative medicine where TB-500’s published mechanism makes it a relevant research tool.
Netherlands
Dutch preclinical research in wound healing and vascular biology incorporates TB-500 into several active programmes. The Netherlands’ proximity to EU logistics infrastructure means EU warehouse shipments arrive in 2–3 business days.
France and Belgium
French research groups in sports medicine and physiotherapy have incorporated TB-500 into injury recovery research. Belgian institutions follow similar programmes in partnership with European research networks.
Technical Specifications
Sequence: Ac-LKKTETQ (7-amino-acid acetylated fragment of thymosin beta-4, positions 17–23)
Molecular formula: C33H54N8O10
Molecular weight: 710.84 g/mol
CAS number: 77591-33-4
Purity (research grade): >99% by HPLC
Appearance: White to off-white lyophilised powder
Storage and reconstitution
Storage (lyophilised):
- Temperature: -20°C
- Stable: 24+ months when properly stored
- Protect from: moisture, light, heat
Reconstitution:
- Solvent: Bac Water (bacteriostatic water, 0.9% benzyl alcohol) — preferred for multi-use vials
- Add 1–2 mL to achieve 5 mg/mL or 2.5 mg/mL respectively
- Reconstituted stability: 28 days at 2–8°C
EU Warehouse Advantage: TB-500 Specifics
TB-500 in lyophilised form is relatively stable compared to some other peptides. However, the customs and logistics risks of UK or non-EU imports still apply:
- Seizure risk — synthetic peptide shipments from the UK attract customs attention in some EU member states
- Delayed transit — extended time in customs storage (uncontrolled temperature/humidity) degrades reconstituted and even lyophilised material over time
- Compliance uncertainty — some EU member states’ customs authorities may request documentation on synthetic peptide imports
EU warehouse sourcing eliminates all of these risks. Internal EU shipments move with the same logistics as any domestic parcel.
TB-500 is available from our EU warehouse in 5 mg and 10 mg formats, with 3–5 day tracked delivery across all EU member states.
Research Use Only. Not for human consumption. TB-500 is a research chemical, not a medicinal product.